Latest electroporation Stories
Despite the sophistication and range of contemporary microscopy techniques, many important biological phenomena still elude the precision of even the most sensitive tools.
PARIS and HOLLISTON, Mass., Dec. 2, 2010 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, and Harvard Apparatus, a division of Harvard Bioscience, Inc.
Laboratory research and clinical studies are beginning to demonstrate that DNA vaccines can be as effective as traditional vaccines, reports Genetic Engineering & Biotechnology News (GEN).
Ichor Medical Systems, whose advanced TriGrid(TM) Delivery System is being tested worldwide for its ability to enhance delivery of DNA drugs and vaccines, announced today that preliminary safety and tolerability data for a Phase I preventive HIV vaccine clinical trial being conducted at the Rockefeller University Hospital in New York City will be presented at the AIDS Vaccine Conference in Cape Town South Africa this week.
VGX Pharmaceuticals (VGX), a developer of DNA vaccines against cancer and infectious diseases that has entered into a definitive merger agreement with Inovio Biomedical (AMEX:INO), announced today that the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), has awarded the company a contract to develop a preventive HIV DNA vaccine candidate in conjunction with VGX's constant current electroporation technology for intradermal...
Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today it has received a contract for $933,000 from the Department of Defense (US Army) to continue research and development of DNA-based vaccines delivered via its proprietary electroporation system.
Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that it achieved positive results from its proprietary research and development program for DNA-based cancer vaccines delivered using the company's electroporation-based DNA delivery technology.
Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using a proprietary electroporation-based DNA delivery platform, announced today it has expanded its research license with the International AIDS Vaccine Initiative (IAVI), a leading organization dedicated to ensuring the development of safe and effective preventive HIV vaccines.